08:46 AM EDT, 08/20/2025 (MT Newswires) -- Agilent Technologies ( A ) said Wednesday its MMR IHC Panel pharmDx has been granted approval by the US Food and Drug Administration as a companion diagnostic test for colorectal cancer.

The test, developed in partnership with Bristol Myers Squibb ( BMY ) , aids in identifying mismatch repair-deficient colorectal cancer patients who are eligible for treatment with Bristol Myers Squibb's ( BMY ) Opdivo alone or in combination with Yervoy, Agilent ( A ) said.

The test is approved for exclusive use with the Agilent Dako Omnis automated staining solution, the company said.